$PFE 

Back to our originally scheduled program - let the positive news cycle begin!

Merck &amp; Co., Inc. - Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Car.. https://t.co/ifpPiQ5jOU